-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-03-27
MTUS:NYE-Metallus Inc (USD)
COMMON STOCK | Others |
Last Closing
USD 22.17Change
+0.56 (+2.59)%Market Cap
N/AVolume
0.29MAnalyst Target
N/AN/A
Verdict
Values as of: 2024-03-27
COMMON STOCK | Others |
Last Closing
USD 22.17Change
+0.56 (+2.59)%Market Cap
N/AVolume
0.29MAnalyst Target
N/AN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
SOJE | SOJE |
N/A |
USD 65.72B |
JEPI | JPMorgan Equity Premium Income.. |
N/A |
USD 32.43B |
DTB | DTB |
N/A |
USD 26.58B |
DFAC | Dimensional U.S. Core Equity 2.. |
N/A |
USD 26.00B |
GBTC | Grayscale Bitcoin Trust (BTC) |
N/A |
USD 23.75B |
JPST | JPMorgan Ultra-Short Income ET.. |
N/A |
USD 22.73B |
SGOV | iShares® 0-3 Month Treasury B.. |
N/A |
USD 19.79B |
AVUV | Avantis® U.S. Small Cap Value.. |
N/A |
USD 10.49B |
DFUV | Dimensional US Marketwide Valu.. |
N/A |
USD 10.15B |
DFAT | Dimensional U.S. Targeted Valu.. |
N/A |
USD 9.40B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
IAK | iShares U.S. Insurance ET.. | 4.79 % | 0.43 % |
N/A |
USD 0.66B |
KIE | SPDR® S&P Insurance ETF | 2.39 % | 0.35 % |
N/A |
USD 0.71B |
EVSTC | 2.10 % | 0.00 % |
N/A |
N/A | |
PXLV | 1.46 % | 0.39 % |
N/A |
N/A | |
OPEN:LSE | iShares Thomson Reuters I.. | 1.45 % | 0.00 % |
N/A |
USD 0.06B |
OPEN:F | iShares VI Public Limited.. | 1.45 % | 0.00 % |
N/A |
USD 0.06B |
OPEN:XETRA | iShares VI Public Limited.. | 1.45 % | 0.00 % |
N/A |
USD 0.06B |
OEW | 1.11 % | 0.40 % |
N/A |
N/A | |
VOE | Vanguard Mid-Cap Value In.. | 1.10 % | 0.07 % |
N/A |
USD 29.18B |
FCTR:LSE | 0.93 % | 0.00 % |
N/A |
N/A | |
USMF:LSE | 0.93 % | 0.00 % |
N/A |
N/A | |
KLCD | 0.87 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | N/A | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | N/A | N/A | N/A | N/A | N/A | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
There is nothing we particularly dislike